ASCO 2025 Insights Into HER2+ Breast Cancer: DESTINY-Breast06, SHR-A1811, Rechallenge With T-DXd Post Grade 1 ILD, and More Podcast Por  arte de portada

ASCO 2025 Insights Into HER2+ Breast Cancer: DESTINY-Breast06, SHR-A1811, Rechallenge With T-DXd Post Grade 1 ILD, and More

ASCO 2025 Insights Into HER2+ Breast Cancer: DESTINY-Breast06, SHR-A1811, Rechallenge With T-DXd Post Grade 1 ILD, and More

Escúchala gratis

Ver detalles del espectáculo

Acerca de esta escucha

Drs. Yuan and Callahan discuss data presented at ASCO 2025 about DESTINY-Breast06, SHR-A1811, and TQB2101, along with real-world data on rechallenging patients with T-DXd post grade 1 ILD.
Todavía no hay opiniones